Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Biologic Endpoints in the Annihilation of Metastases for Oligometastasis (BEAM ON)

NCT01706432 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT01706432
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01706432 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Biologic Endpoints in the Annihilation of Metastases for Oligometastasis (BEAM ON)
Lead sponsor
University of Chicago
Phase
Observational
Overall status
Completed
Start date
June 15, 2009
Completion date
January 22, 2024
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

central nervous system metastases, invasive ductal breast carcinoma, invasive ductal breast carcinoma with predominant intraductal component, invasive lobular breast carcinoma, invasive lobular breast carcinoma with predominant in situ component, liver metastases, lobular breast carcinoma in situ, lung metastases, male breast cancer, medullary ductal breast carcinoma with lymphocytic infiltrate, mucinous ductal breast carcinoma, papillary ductal breast carcinoma, recurrent breast cancer, stage iv breast cancer, tubular ductal breast carcinoma, tumors metastatic to brain